ArticleFrontiers in immunology2022

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.

Weixiang Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.